AbbVie Highlights Real-World Data Supporting VRAYLAR® Effectiveness at Psych Congress 2026
AbbVie Presents New VRAYLAR Data Highlighting Real-World Outcomes in Depression and Bipolar I Disorder AbbVie (NYSE: ABBV) has presented new data for VRAYLAR® (cariprazine) at Psych Congress 2026 in New…
Novo’s FREHEMGO® Receives Positive CHMP Recommendation for Hemophilia A
Novo Nordisk’s FREHEMGO Receives Positive CHMP Opinion for Haemophilia A Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)…
Lilly to Present New Foundayo, Retatrutide and EloraTZP Data at EASD 2026
Lilly to Present New Cardiometabolic Data on Foundayo, Retatrutide and EloraTZP at EASD 2026 Eli Lilly and Company (NYSE: LLY), the manufacturer of Zepbound® (tirzepatide), Mounjaro® (tirzepatide) and Foundayo® (orforglipron),…
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib
IMPACT Therapeutics’ Senaparib Receives Positive EMA CHMP Opinion for Ovarian Cancer Maintenance Treatment IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on developing targeted anti-cancer therapies based on synthetic lethality…
Largest Lung Cancer MRD Study Highlights Strong Prognostic Value of Signatera™
Largest Lung Cancer MRD Study Demonstrates Signatera™’s Strong Prognostic Value Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, has announced new clinical data presented…
LEO Pharma Gains FDA Priority Review for Dersimelagon NDA and Completes Tanabe Pharma Acquisition
LEO Pharma Gains FDA Priority Review for Dersimelagon NDA Following Acquisition of Global Rights LEO Pharma, a global leader in medical dermatology, has announced two significant developments for dersimelagon, an…
MaaT Pharma Updates MaaT013 Development Plan Following Negative CHMP Opinion
MaaT Pharma Reports CHMP Maintains Negative Opinion on MaaT013 for Acute Graft-versus-Host Disease MaaT Pharma (Euronext: MAAT), a clinical-stage biotechnology company developing Microbiome Ecosystem Therapies™ (MET) designed to modulate the…
Sensorion Announces Details for SENS-601 Program Day on September 22, 2026
Sensorion to Host SENS-601 Program Day on GJB2-Related Hearing Loss Gene Therapy Sensorion (FR001401A9Z0 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies designed to restore, treat, and…
Takeda Employees Select Four Global CSR Collaborations to Advance Climate-Resilient Health Systems
Takeda Awards $22.2 Million to Four Global CSR Partners to Strengthen Climate-Resilient Health Systems Takeda (TSE: 4502/NYSE: TAK) has announced a total commitment of $22.2 million to four new Global…
PAHO-Gilead HIV Prevention Deal in Latin America Welcomed by AHF as Civil Society Victory
PAHO-Gilead HIV Prevention Deal in Latin America Welcomed by AHF as Civil Society Victory AIDS Healthcare Foundation (AHF), one of the world’s largest HIV/AIDS healthcare organizations, has welcomed a new…
Puma Biotechnology Initiates Phase II ALISCA®-Lung2 Trial of Alisertib Plus Paclitaxel in Advanced Small Cell Lung Cancer
Puma Biotechnology Initiates Phase II ALISCA®-Lung2 Trial of Alisertib and Paclitaxel in Advanced Small Cell Lung Cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company focused on developing innovative cancer…
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Faeth Therapeutics Appoints Cancer Biology Expert Karen Vousden, Ph.D., to Board of Directors Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company developing therapies designed to improve outcomes for cancer…